Skip to main content

Table 3 Primary and secondary outcomes (Intention-to-treat analysis, n = 67)

From: Effects of vaginal administration of conjugated estrogens tablet on sexual function in postmenopausal women with sexual dysfunction: a double-blind, randomized, placebo-controlled trial

Parameter

Estrogens group* (n = 34)

Placebo group (n = 33)

P-value

Week 0

Week 12

Week 0

Week 12

FSFI: Total a

20.31 ± 4.93

25.14 ± 4.74

22.27 ± 5.03

24.32 ± 4.83

0.182

 FSFI: Desire a

2.44 ± 0.82

3.12 ± 0.76

2.73 ± 0.65

2.90 ± 0.64

0.218

 FSFI: Arousal a

2.72 ± 1.06

3.46 ± 0.97

3.03 ± 1.28

3.25 ± 0.91

0.133

 FSFI: Lubrication a

3.46 ± 1.27

4.54 ± 1.16

3.98 ± 1.04

4.20 ± 1.03

0.057

 FSFI: Orgasm a

3.93 ± 1.14

4.26 ± 1.24

4.10 ± 1.12

4.62 ± 1.16

0.365

 FSFI: Satisfaction a

4.06 ± 1.02

4.63 ± 0.88

4.52 ± 0.85

4.69 ± 0.99

0.219

 FSFI: Pain a

3.71 ± 1.87

5.13 ± 0.95

3.90 ± 1.51

4.66 ± 1.05

0.067

Vaginal pHc

6.0 (5.5–8.0)

5.0 (4.0–6.0)

6.0 (5.5–6.0)

7.0 (6.0–8.0)

< 0.001

Normal Flora Indexc

5 (3–6)

6 (4–10)

4 (3–6)

6 (4–6)

0.282

Vaginal Maturation Valuec

15 (0–53.75)

57.5 (38.75–65)

20 (1.25–51.25)

20 (0.63–46.88)

< 0.001

Superficial cellc

0 (0–1)

0.5 (1.5–3)

0 (0–2.5)

0 (0–0.88)

< 0.001

MBS, totalc

4 (3–6)

2 (0–3)

5 (3–7)

3 (1–4)

0.182

 Vaginal drynessc

2 (2–3)

1 (0–2)

2 (2–3)

1 (0–2)

0.858

 Vaginal/vulvar irritation/itchingc

0 (0–2)

0 (0–0)

1 (0–2)

0 (0–1)

0.190

 vaginal/vulvar sorenessc

0 (0–1)

0 (0–0)

0 (0–2)

0 (0–1)

0.204

 Dyspareuniac

2 (1–3)

0 (0–1)

2 (1–2)

1 (0–1)

0.152

  1. *conjugated estrogens
  2. amean ± SD Data was analyzed by ANCOVA, bnumber (%), cmedian (interquartile range, IQR) Data was analyzed by Mann-Whitney U test
  3. Data shown in bold indicates statistical significance (p < 0.05)
  4. FSFI the Female Sexual Function Index, MBS Most Bothersome Symptoms